Cancer Gene Discovery

Past to Present

Christopher R. Clark, Willa W Durose, Tim Starr

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Cancer is a complex disease that originates from genetic changes leading to multiple phenotypic manifestations that ultimately result in suffering and death from cancer. Attempts have been made to define the phenotypic and genetic “hallmarks” of cancer, but many of these “hallmarks” remain descriptive, while the underlying mechanisms responsible for these hallmarks remain elusive. For decades, cancer researchers have been methodically identifying the molecular mechanisms that result in tumor initiation, growth, metastases, and resistance to therapy. Great strides forward have been made and we are entering an era of “precision medicine” with the goal of treating each cancer based on its unique etiology. Increasingly, the decision to use targeted therapies and immunotherapies in the clinic is based on the genotype of the cancer being treated. For example, specific tyrosine kinase inhibitors are only prescribed to patients that express the tyrosine kinase protein on their cancer cells. Likewise, a genetically unstable cancer is predictive for successful immunotherapy. Knowledge of the specific genetic changes that result in overproduction of oncogenes and reduced production of tumor suppressors is crucial for advancing therapeutic options for cancer. The first chapter of this book presents a brief history of cancer gene discovery. In the remaining chapters of this book, we present protocols using in silico, in vitro, and in vivo techniques for identifying genetic drivers of cancer, in the hope that these protocols will be used to increase our knowledge of the molecular mechanisms driving cancer.

Original languageEnglish (US)
Title of host publicationMethods in Molecular Biology
PublisherHumana Press Inc.
Pages1-15
Number of pages15
DOIs
StatePublished - Jan 1 2019

Publication series

NameMethods in Molecular Biology
Volume1907
ISSN (Print)1064-3745

Fingerprint

Neoplasm Genes
Genetic Association Studies
Neoplasms
Protein-Tyrosine Kinases
Immunotherapy
Genetic Techniques
Precision Medicine
Inborn Genetic Diseases
Oncogenes
Psychological Stress
Computer Simulation
Therapeutics
Genotype

Keywords

  • Chromosomal engineering
  • Forward genetic screens
  • History of cancer gene discovery
  • Insertional mutagenesis

Cite this

Clark, C. R., Durose, W. W., & Starr, T. (2019). Cancer Gene Discovery: Past to Present. In Methods in Molecular Biology (pp. 1-15). (Methods in Molecular Biology; Vol. 1907). Humana Press Inc.. https://doi.org/10.1007/978-1-4939-8967-6_1

Cancer Gene Discovery : Past to Present. / Clark, Christopher R.; Durose, Willa W; Starr, Tim.

Methods in Molecular Biology. Humana Press Inc., 2019. p. 1-15 (Methods in Molecular Biology; Vol. 1907).

Research output: Chapter in Book/Report/Conference proceedingChapter

Clark, CR, Durose, WW & Starr, T 2019, Cancer Gene Discovery: Past to Present. in Methods in Molecular Biology. Methods in Molecular Biology, vol. 1907, Humana Press Inc., pp. 1-15. https://doi.org/10.1007/978-1-4939-8967-6_1
Clark CR, Durose WW, Starr T. Cancer Gene Discovery: Past to Present. In Methods in Molecular Biology. Humana Press Inc. 2019. p. 1-15. (Methods in Molecular Biology). https://doi.org/10.1007/978-1-4939-8967-6_1
Clark, Christopher R. ; Durose, Willa W ; Starr, Tim. / Cancer Gene Discovery : Past to Present. Methods in Molecular Biology. Humana Press Inc., 2019. pp. 1-15 (Methods in Molecular Biology).
@inbook{c071eced55b44f599b5667fc9f31e919,
title = "Cancer Gene Discovery: Past to Present",
abstract = "Cancer is a complex disease that originates from genetic changes leading to multiple phenotypic manifestations that ultimately result in suffering and death from cancer. Attempts have been made to define the phenotypic and genetic “hallmarks” of cancer, but many of these “hallmarks” remain descriptive, while the underlying mechanisms responsible for these hallmarks remain elusive. For decades, cancer researchers have been methodically identifying the molecular mechanisms that result in tumor initiation, growth, metastases, and resistance to therapy. Great strides forward have been made and we are entering an era of “precision medicine” with the goal of treating each cancer based on its unique etiology. Increasingly, the decision to use targeted therapies and immunotherapies in the clinic is based on the genotype of the cancer being treated. For example, specific tyrosine kinase inhibitors are only prescribed to patients that express the tyrosine kinase protein on their cancer cells. Likewise, a genetically unstable cancer is predictive for successful immunotherapy. Knowledge of the specific genetic changes that result in overproduction of oncogenes and reduced production of tumor suppressors is crucial for advancing therapeutic options for cancer. The first chapter of this book presents a brief history of cancer gene discovery. In the remaining chapters of this book, we present protocols using in silico, in vitro, and in vivo techniques for identifying genetic drivers of cancer, in the hope that these protocols will be used to increase our knowledge of the molecular mechanisms driving cancer.",
keywords = "Chromosomal engineering, Forward genetic screens, History of cancer gene discovery, Insertional mutagenesis",
author = "Clark, {Christopher R.} and Durose, {Willa W} and Tim Starr",
year = "2019",
month = "1",
day = "1",
doi = "10.1007/978-1-4939-8967-6_1",
language = "English (US)",
series = "Methods in Molecular Biology",
publisher = "Humana Press Inc.",
pages = "1--15",
booktitle = "Methods in Molecular Biology",

}

TY - CHAP

T1 - Cancer Gene Discovery

T2 - Past to Present

AU - Clark, Christopher R.

AU - Durose, Willa W

AU - Starr, Tim

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Cancer is a complex disease that originates from genetic changes leading to multiple phenotypic manifestations that ultimately result in suffering and death from cancer. Attempts have been made to define the phenotypic and genetic “hallmarks” of cancer, but many of these “hallmarks” remain descriptive, while the underlying mechanisms responsible for these hallmarks remain elusive. For decades, cancer researchers have been methodically identifying the molecular mechanisms that result in tumor initiation, growth, metastases, and resistance to therapy. Great strides forward have been made and we are entering an era of “precision medicine” with the goal of treating each cancer based on its unique etiology. Increasingly, the decision to use targeted therapies and immunotherapies in the clinic is based on the genotype of the cancer being treated. For example, specific tyrosine kinase inhibitors are only prescribed to patients that express the tyrosine kinase protein on their cancer cells. Likewise, a genetically unstable cancer is predictive for successful immunotherapy. Knowledge of the specific genetic changes that result in overproduction of oncogenes and reduced production of tumor suppressors is crucial for advancing therapeutic options for cancer. The first chapter of this book presents a brief history of cancer gene discovery. In the remaining chapters of this book, we present protocols using in silico, in vitro, and in vivo techniques for identifying genetic drivers of cancer, in the hope that these protocols will be used to increase our knowledge of the molecular mechanisms driving cancer.

AB - Cancer is a complex disease that originates from genetic changes leading to multiple phenotypic manifestations that ultimately result in suffering and death from cancer. Attempts have been made to define the phenotypic and genetic “hallmarks” of cancer, but many of these “hallmarks” remain descriptive, while the underlying mechanisms responsible for these hallmarks remain elusive. For decades, cancer researchers have been methodically identifying the molecular mechanisms that result in tumor initiation, growth, metastases, and resistance to therapy. Great strides forward have been made and we are entering an era of “precision medicine” with the goal of treating each cancer based on its unique etiology. Increasingly, the decision to use targeted therapies and immunotherapies in the clinic is based on the genotype of the cancer being treated. For example, specific tyrosine kinase inhibitors are only prescribed to patients that express the tyrosine kinase protein on their cancer cells. Likewise, a genetically unstable cancer is predictive for successful immunotherapy. Knowledge of the specific genetic changes that result in overproduction of oncogenes and reduced production of tumor suppressors is crucial for advancing therapeutic options for cancer. The first chapter of this book presents a brief history of cancer gene discovery. In the remaining chapters of this book, we present protocols using in silico, in vitro, and in vivo techniques for identifying genetic drivers of cancer, in the hope that these protocols will be used to increase our knowledge of the molecular mechanisms driving cancer.

KW - Chromosomal engineering

KW - Forward genetic screens

KW - History of cancer gene discovery

KW - Insertional mutagenesis

UR - http://www.scopus.com/inward/record.url?scp=85058610287&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85058610287&partnerID=8YFLogxK

U2 - 10.1007/978-1-4939-8967-6_1

DO - 10.1007/978-1-4939-8967-6_1

M3 - Chapter

T3 - Methods in Molecular Biology

SP - 1

EP - 15

BT - Methods in Molecular Biology

PB - Humana Press Inc.

ER -